Youssef Rddad on Muck Rack

Youssef Rddad

Verified
Seattle
As seen in: Oncology News Central, MSN, Fox News, The Washington Post, TIME, Los Angeles Times, Yahoo Finance, Associated Press, Chicago Tribune, SFGate, Stuff.co.nz and
Journalist, composer, @theadvocatebr, @arkansasonline and @AP alumn.

Get in touch with Youssef

Contact Youssef, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Youssef Rddad’s Journalist Portfolio

See all →
As coronavirus left Louisiana nursing homes short-staffed, some residents were left without care

As coronavirus left Louisiana nursing homes short-staffed, some residents were left without care

The Louisiana Investigative Journalism Fund Investigative reporting is more essential than ever, which is why…

View article →
Feds detail indictment of Arkansas white supremacist group; leaders oversaw violent crimes, prose...

Feds detail indictment of Arkansas white supremacist group; leaders oversaw violent crimes, prose...

Dozens of people with ties to a white supremacy group were charged with operating a drug trafficking operatio…

View article →
Behind Minnesota's opioid epidemic, a second drug scourge?

Behind Minnesota's opioid epidemic, a second drug scourge?

A sharp increase in the use of anti-anxiety drugs such as Valium and Xanax is raising concerns among Twin Cit…

View article →
Documents: Little Rock officer said he 'blacked out' during man's fatal shooting

Documents: Little Rock officer said he 'blacked out' during man's fatal shooting

The Little Rock Police Department released its investigative report into a police officer who fatally shot 30…

View article →
Woodbury police who mistakenly shot man in standoff ask for lawsuit dismissal

Woodbury police who mistakenly shot man in standoff ask for lawsuit dismissal

Attorneys for three Woodbury police officers who mistakenly shot and killed a St. Paul man are asking a feder…

View article →
East Feliciana deputy who fatally shot man was previously fired following domestic abuse claim

East Feliciana deputy who fatally shot man was previously fired following domestic abuse claim

A part-time East Feliciana deputy who shot and killed a man suspected of stealing raw chicken from a convenie…

View article →

Articles

Despite Breast Cancer Advances at ASCO 2026, “A Lot of Unanswered Questions” Remain

|
By Youssef Rddad Verified
| Oncology News Central Verified
The 2026 American Society of Clinical Oncology (ASCO) Annual Meeting offered new insights into genomic risk assessment, endocrine therapy sequencing, and the expanding treatment landscape for metastatic disease in estrogen receptor (ER)-positive, HER2-negative breast cancer. Among the studies that drew attention was SERENA-6, which showed a benefit with switching to camizestrant after detection of an ESR1 mutation by circulating tumor DNA (ctDNA).
Open in Who Shared Issue with article?

FDA Approves Combo Regimen for HR-Positive, HER2-Positive Breast Cancer

|
By Youssef Rddad Verified
| Oncology News Central Verified
On June 24, the U.S. Food and Drug Administration (FDA) approved the combination of palbociclib (Ibrance) plus trastuzumab, with or without pertuzumab (Perjeta), and endocrine therapy as a maintenance treatment for adults with hormone receptor (HR)-positive, HER2-positive locally advanced or metastatic breast cancer after induction therapy. Regulators based their decision on results from the randomized, open-label PATINA clinical trial.
Open in Who Shared Issue with article?

ADC Gets FDA Approval for Two Triple-Negative Breast Cancer Indications

|
By Youssef Rddad Verified
| Oncology News Central Verified
On June 24, the U.S. Food and Drug Administration (FDA) approved two separate indications for sacituzumab govitecan-hziy (Trodelvy) in adults with triple-negative breast cancer (TNBC) in both the refractory and first-line settings. The first indication is for monotherapy sacituzumab govitecan in adults with unresectable locally advanced or metastatic TNBC who are not eligible for PD-1 or PD-L1 inhibitor-based therapy.
Open in Who Shared Issue with article?
See all 3,271 licensed articles (3,486 Total)
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified